Issues

Journal & Issues

AHEAD OF PRINT

Volume 69 (2022): Issue 2 (August 2022)

Volume 69 (2022): Issue 1 (January 2022)

Volume 69 (2022): Issue s1 (July 2022)

Volume 68 (2021): Issue 2 (December 2021)

Volume 68 (2021): Issue 1 (January 2021)

Volume 67 (2020): Issue 2 (May 2020)

Volume 67 (2020): Issue 1 (January 2020)

Volume 66 (2019): Issue 2 (November 2019)

Volume 66 (2019): Issue 1 (June 2019)

Volume 65 (2018): Issue 2 (November 2018)

Volume 65 (2018): Issue 1 (June 2018)

Volume 64 (2017): Issue 2 (November 2017)

Volume 64 (2017): Issue 1 (September 2017)

Volume 63 (2016): Issue s12 (December 2016)

Volume 63 (2016): Issue 2 (December 2016)

Volume 63 (2016): Issue 1 (September 2016)

Volume 62 (2015): Issue s10 (September 2015)

Volume 62 (2015): Issue s9 (June 2015)

Volume 62 (2015): Issue 2 (December 2015)

Volume 62 (2015): Issue 1 (June 2015)

Volume 61 (2014): Issue 2 (December 2014)

Volume 61 (2014): Issue 1 (August 2014)

Volume 60 (2013): Issue Supplementum-VIII (March 2013)
Rare disease day in Slovakia, Europlan national conference

Volume 60 (2013): Issue 2 (December 2013)

Volume 60 (2013): Issue 1 (June 2013)

Volume 59 (2012): Issue Supplement-VI (January 2012)
Clinical Pharmacy in the Slovak Republic, dedicated to the associated professor Lívia Magulová, PhD.

Volume 59 (2012): Issue Supplement-VII (February 2012)
Conference abstracts, Rare disease day, conference 29.2.2012, First Slovak conference about rare diseases

Volume 59 (2012): Issue 2 (November 2012)

Volume 59 (2012): Issue 1 (June 2012)

Volume 58 (2011): Issue 1 (January 2011)

Journal Details
Format
Journal
eISSN
2453-6725
First Published
25 Nov 2011
Publication timeframe
2 times per year
Languages
English

Search

Volume 69 (2022): Issue s1 (July 2022)

Journal Details
Format
Journal
eISSN
2453-6725
First Published
25 Nov 2011
Publication timeframe
2 times per year
Languages
English

Search

6 Articles
Open Access

Presentations

Published Online: 22 Jun 2022
Page range: 1 - 28

Abstract

Open Access

Posters

Published Online: 18 Jun 2022
Page range: 29 - 78

Abstract

Open Access

Secondary prevention of patients with ischaemic stroke after recanalization treatment

Published Online: 13 Jul 2022
Page range: 79 - 81

Abstract

Abstract

We performed a retrospective analysis of 100 patients with ischaemic stroke. All patients underwent intravenous thrombolysis in the acute care setting (avg. 2.8 hours, max 4.5 hours) and 10 of them also underwent mechanical thrombectomy. For 20% of the patients, the stroke was fatal. Door to needle time was 38.46 minutes. Although changes in antithrombotic treatment were introduced due to strokes, there was no significant difference in National Institute of Health Stroke Scale scores between the patients who were on antithrombotic treatment and those who were on no antithrombotic treatment.

Keywords

  • ischaemic stroke
  • secondary prevention
  • antiplatelet therapy
  • anticoagulant therapy
  • intravenous thrombolysis
Open Access

Endocrine changes in women with a medically indicated abortion: the study design

Published Online: 25 Jun 2022
Page range: 82 - 83

Abstract

Abstract

A strongly psychosocially demanding situation in the life of a woman is the option of medically indicated abortion. Here we present the design of an ongoing study aiming to examine the stressfulness of life events related to medically indicated abortions by measuring cortisol concentrations in the participants’ hair and saliva. Pilot results show high salivary cortisol concentrations in the majority of the women one day before induced abortion. In half of the group, two months after the abortion, hair cortisol concentrations were higher in comparison to cumulative values from two months before. There were no changes in the second half.

Keywords

  • medically indicated abortion
  • cortisol
  • stress
  • clinical trial
Open Access

Immune-Mediated Adverse Effects of Checkpoint Inhibitors: A Clinical Experience

Published Online: 18 Jun 2022
Page range: 84 - 86

Abstract

Abstract

Autoimmune adverse effects of immune checkpoint inhibitors (ICIs) are rare but may be life-threatening. We performed a retrospective analysis of the immune-related adverse effects (irAEs) of ICIs in the Masaryk Memorial Cancer Institute (MMCI) from 2011 to 2021. The ICIs were administered to 648 patients. Severe irAEs were pronounced in 83 patients (12.8 %). Further, we report a case of severe irAE after treatment with ipilimumab and nivolumab. Prednisone, mesalazine, octreotide, infliximab, vedolizumab, and mycophenolate mofetil were used to manage G4 colitis, with partial response. Early diagnosis and appropriate management of irAE are essential in the perspective of further oncological treatment.

Keywords

  • Immune checkpoint inhibitors
  • immunotherapy
  • adverse effect
  • autoimmunity
Open Access

Optimisation of flow cytometric detection of intracellular SLAMF receptor-associated adaptor proteins SAP and EAT-2

Published Online: 18 Jun 2022
Page range: 87 - 89

Abstract

Abstract

SAP and EAT-2 are intracellular adaptor proteins that link SLAMF receptors to downstream intracellular signalling pathways. Their expression and functions vary among different types of hematopoietic cells. The roles of SAP and EAT-2 in haematological malignancies are poorly understood. Here, we attempted to optimise a method for the detection of intracellular SAP and EAT-2 by flow cytometry. We found that using PerFix EXPOSE kit for cell fixation and permeabilization ensures optimal results in terms of staining intensity and signal-to-noise ratio.

Keywords

  • SLAMF receptors
  • SAP
  • EAT-2
  • lymphocytes
  • flow cytometry
6 Articles
Open Access

Presentations

Published Online: 22 Jun 2022
Page range: 1 - 28

Abstract

Open Access

Posters

Published Online: 18 Jun 2022
Page range: 29 - 78

Abstract

Open Access

Secondary prevention of patients with ischaemic stroke after recanalization treatment

Published Online: 13 Jul 2022
Page range: 79 - 81

Abstract

Abstract

We performed a retrospective analysis of 100 patients with ischaemic stroke. All patients underwent intravenous thrombolysis in the acute care setting (avg. 2.8 hours, max 4.5 hours) and 10 of them also underwent mechanical thrombectomy. For 20% of the patients, the stroke was fatal. Door to needle time was 38.46 minutes. Although changes in antithrombotic treatment were introduced due to strokes, there was no significant difference in National Institute of Health Stroke Scale scores between the patients who were on antithrombotic treatment and those who were on no antithrombotic treatment.

Keywords

  • ischaemic stroke
  • secondary prevention
  • antiplatelet therapy
  • anticoagulant therapy
  • intravenous thrombolysis
Open Access

Endocrine changes in women with a medically indicated abortion: the study design

Published Online: 25 Jun 2022
Page range: 82 - 83

Abstract

Abstract

A strongly psychosocially demanding situation in the life of a woman is the option of medically indicated abortion. Here we present the design of an ongoing study aiming to examine the stressfulness of life events related to medically indicated abortions by measuring cortisol concentrations in the participants’ hair and saliva. Pilot results show high salivary cortisol concentrations in the majority of the women one day before induced abortion. In half of the group, two months after the abortion, hair cortisol concentrations were higher in comparison to cumulative values from two months before. There were no changes in the second half.

Keywords

  • medically indicated abortion
  • cortisol
  • stress
  • clinical trial
Open Access

Immune-Mediated Adverse Effects of Checkpoint Inhibitors: A Clinical Experience

Published Online: 18 Jun 2022
Page range: 84 - 86

Abstract

Abstract

Autoimmune adverse effects of immune checkpoint inhibitors (ICIs) are rare but may be life-threatening. We performed a retrospective analysis of the immune-related adverse effects (irAEs) of ICIs in the Masaryk Memorial Cancer Institute (MMCI) from 2011 to 2021. The ICIs were administered to 648 patients. Severe irAEs were pronounced in 83 patients (12.8 %). Further, we report a case of severe irAE after treatment with ipilimumab and nivolumab. Prednisone, mesalazine, octreotide, infliximab, vedolizumab, and mycophenolate mofetil were used to manage G4 colitis, with partial response. Early diagnosis and appropriate management of irAE are essential in the perspective of further oncological treatment.

Keywords

  • Immune checkpoint inhibitors
  • immunotherapy
  • adverse effect
  • autoimmunity
Open Access

Optimisation of flow cytometric detection of intracellular SLAMF receptor-associated adaptor proteins SAP and EAT-2

Published Online: 18 Jun 2022
Page range: 87 - 89

Abstract

Abstract

SAP and EAT-2 are intracellular adaptor proteins that link SLAMF receptors to downstream intracellular signalling pathways. Their expression and functions vary among different types of hematopoietic cells. The roles of SAP and EAT-2 in haematological malignancies are poorly understood. Here, we attempted to optimise a method for the detection of intracellular SAP and EAT-2 by flow cytometry. We found that using PerFix EXPOSE kit for cell fixation and permeabilization ensures optimal results in terms of staining intensity and signal-to-noise ratio.

Keywords

  • SLAMF receptors
  • SAP
  • EAT-2
  • lymphocytes
  • flow cytometry

Plan your remote conference with Sciendo